Related Experiment Video
Updated: Jun 8, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Glycaemic control with liraglutide: the phase 3 trial programme.
1University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. Philip.Raskin@utsouthwestern.edu
International Journal of Clinical Practice. Supplement
|October 5, 2010
Summary
Liraglutide effectively lowers blood sugar (HbA1c) in type 2 diabetes patients, showing sustained results with a low risk of hypoglycemia. This makes it a promising treatment option.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management requires effective therapies to achieve glycemic control and prevent complications.
- Liraglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a therapeutic option for T2DM.
Purpose of the Study:
- To evaluate the efficacy and safety of liraglutide in phase 3 clinical trials, with a primary focus on glycemic control.
- To compare liraglutide's effects on glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG) against other antidiabetic agents.
Main Methods:
- Systematic review of phase 3 clinical trial data for liraglutide in patients with type 2 diabetes.
- Analysis of changes in HbA1c, FPG, and PPG levels from baseline.
- Assessment of hypoglycemic event rates (minor and major) and other adverse events.
Main Results:
- Liraglutide demonstrated significant reductions in HbA1c (up to 1.5%), FPG (up to -2.4 mmol/l), and PPG (up to -2.7 mmol/l) compared to sitagliptin, glimepiride, rosiglitazone, insulin glargine, and exenatide.
- Glycemic improvements were sustained for up to 52 weeks.
- Liraglutide showed significantly lower rates of minor hypoglycemia than glimepiride and exenatide; major hypoglycemia was rare and associated with sulfonylurea combination therapy. Nausea was the most common side effect, subsiding early.
Conclusions:
- Liraglutide provides effective and sustained glycemic control in type 2 diabetes patients.
- It is suitable for use across the care continuum and is associated with generally low rates of minor hypoglycemia, though risk increases with sulfonylurea use.
- Liraglutide represents a valuable new therapeutic option for managing type 2 diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...